Related Experiment Video
Updated: Aug 8, 2026
04:28
Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
Published on: March 23, 2016
ALSUntangled #84 - ivermectin
Benjamin Helmold1, Carmel Armon2, Michael Benatar3
1Medical School, Duke University, Durham, NC, USA.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|August 6, 2026
Summary
Ivermectin shows potential for amyotrophic lateral sclerosis (ALS) due to its anti-inflammatory properties. However, current evidence, including preclinical studies and limited patient data, does not support its use for slowing ALS progression.
Area of Science:
- Neurology
- Pharmacology
Background:
- Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
- Alternative and off-label treatments are explored for ALS management.
- Ivermectin is investigated for its potential neuroprotective effects.
Purpose of the Study:
- To review the evidence for ivermectin as a treatment to slow ALS progression.
- To assess the plausibility of ivermectin's mechanisms in ALS.
Main Methods:
- Literature review of preclinical studies and patient data.
- Analysis of ivermectin's pharmacokinetic properties and safety profile in ALS.
Main Results:
- One preclinical study showed ivermectin extended lifespan in a mouse model of ALS, but this was not replicated.
- Two patients with ALS showed no benefit from ivermectin.
- No clinical trials of ivermectin in ALS patients were found.
Conclusions:
- Ivermectin has plausible mechanisms for ALS treatment, including modulation of neuroinflammation and excitotoxicity.
- Current evidence does not support the use of ivermectin for ALS.
- Further research is needed to establish safety and efficacy in ALS patients.
Related Concept Videos
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...